The Myelodysplastic Syndromes (MDS) Foundation says data published in the peer reviewed medical journal The Lancet Oncology confirms VIDAZA extends survival for patients with higher-risk MDS. Myelodysplastic syndromes are a group of blood-related malignancies that are difficult to treat and in higher-risk patients have a median survival rate of less than one year. Symptoms include anemia and fatigue, and often patients must rely on blood transfusions to manage the symptoms. VIDAZA, also known by its chemical name, azacitidine, represents a new approach to treatment with important benefits for patients with MDS, and a related condition called acute myeloid leukemia (AML).
To view Multimedia News Release go to http://www.prnewswire.com/mnr/mds-foundation/37124/